[go: up one dir, main page]

WO2019098759A3 - 형질전환된 인간세포 및 이의 용도 - Google Patents

형질전환된 인간세포 및 이의 용도 Download PDF

Info

Publication number
WO2019098759A3
WO2019098759A3 PCT/KR2018/014112 KR2018014112W WO2019098759A3 WO 2019098759 A3 WO2019098759 A3 WO 2019098759A3 KR 2018014112 W KR2018014112 W KR 2018014112W WO 2019098759 A3 WO2019098759 A3 WO 2019098759A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
transformed
human cell
mhc
transformed human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/014112
Other languages
English (en)
French (fr)
Other versions
WO2019098759A2 (ko
Inventor
임옥재
김문경
이윤정
이지원
양우석
김유영
권영은
최승현
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Institute for Biomedical Research
Original Assignee
Mogam Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2020527057A priority Critical patent/JP2021503284A/ja
Priority to US16/764,664 priority patent/US20200407713A1/en
Priority to CN201880074666.8A priority patent/CN111742049A/zh
Priority to KR1020207011903A priority patent/KR20200074954A/ko
Priority to AU2018367792A priority patent/AU2018367792A1/en
Priority to EP18877963.1A priority patent/EP3712268A4/en
Priority to MX2020005235A priority patent/MX2020005235A/es
Priority to CA3082331A priority patent/CA3082331A1/en
Application filed by Mogam Institute for Biomedical Research filed Critical Mogam Institute for Biomedical Research
Priority to SG11202004529XA priority patent/SG11202004529XA/en
Publication of WO2019098759A2 publication Critical patent/WO2019098759A2/ko
Publication of WO2019098759A3 publication Critical patent/WO2019098759A3/ko
Priority to IL274691A priority patent/IL274691A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 형질전환된 인간세포 및 이의 용도에 관한 것으로, 보다 구체적으로 가이드 RNA를 이용한 유전자 발현 억제용 시스템을 이용한 MHC I 세포막 수용체 및 MHC II 세포막 수용체를 코딩하는 유전자가 변형된 세포 및 이의 용도에 관한 것이다. 상기와 같은 형질전환 세포는 생체 내에서도 세포의 치료 효능을 효과적으로 발휘할 수 있으며, 생체 내 면역반응에 의해 제거되지 않는다. 따라서, 상기 면역세포를 유효성분으로 포함하는 조성물은 암, 감염성 질환, 퇴행성 질환 또는 면역 질환 치료에 유용하게 활용될 수 있을 것으로 기대된다.
PCT/KR2018/014112 2017-11-16 2018-11-16 형질전환된 인간세포 및 이의 용도 Ceased WO2019098759A2 (ko)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2020005235A MX2020005235A (es) 2017-11-16 2018-11-16 Celula humana transformada y uso de la misma.
CN201880074666.8A CN111742049A (zh) 2017-11-16 2018-11-16 转化的人细胞及其用途
KR1020207011903A KR20200074954A (ko) 2017-11-16 2018-11-16 형질전환된 인간세포 및 이의 용도
AU2018367792A AU2018367792A1 (en) 2017-11-16 2018-11-16 Transformed human cell and use thereof
EP18877963.1A EP3712268A4 (en) 2017-11-16 2018-11-16 TRANSFORMED HUMAN CELL AND ITS USE
JP2020527057A JP2021503284A (ja) 2017-11-16 2018-11-16 形質転換ヒト細胞およびその使用
US16/764,664 US20200407713A1 (en) 2017-11-16 2018-11-16 Transformed human cell and use thereof
CA3082331A CA3082331A1 (en) 2017-11-16 2018-11-16 Transformed human cell and use thereof
SG11202004529XA SG11202004529XA (en) 2017-11-16 2018-11-16 Transformed human cell and use thereof
IL274691A IL274691A (en) 2017-11-16 2020-05-14 Transformed human cells inhibited for expression of mhc i and mhc ii cell membrane receptors and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587068P 2017-11-16 2017-11-16
US62/587,068 2017-11-16

Publications (2)

Publication Number Publication Date
WO2019098759A2 WO2019098759A2 (ko) 2019-05-23
WO2019098759A3 true WO2019098759A3 (ko) 2019-07-18

Family

ID=66537875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/014112 Ceased WO2019098759A2 (ko) 2017-11-16 2018-11-16 형질전환된 인간세포 및 이의 용도

Country Status (11)

Country Link
US (1) US20200407713A1 (ko)
EP (1) EP3712268A4 (ko)
JP (1) JP2021503284A (ko)
KR (1) KR20200074954A (ko)
CN (1) CN111742049A (ko)
AU (1) AU2018367792A1 (ko)
CA (1) CA3082331A1 (ko)
IL (1) IL274691A (ko)
MX (1) MX2020005235A (ko)
SG (1) SG11202004529XA (ko)
WO (1) WO2019098759A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
AU2020340622A1 (en) 2019-09-05 2022-03-03 Crispr Therapeutics Ag Universal donor cells
WO2022006309A1 (en) * 2020-07-03 2022-01-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions for editing the b2m locus in b cells
KR20220005208A (ko) * 2020-07-06 2022-01-13 주식회사 지씨셀 면역원성이 감소된 신규한 이식용 세포
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4259160A4 (en) * 2020-12-14 2025-05-14 Emendobio Inc. BIALLELIC INACTIVATION OF B2M
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
AU2021414405A1 (en) 2020-12-31 2023-08-10 Crispr Therapeutics Ag Universal donor cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160018425A (ko) * 2014-08-06 2016-02-17 차의과학대학교 산학협력단 조직적합성항원 유전자들의 교정을 통하여 구축한, 면역적합형 세포
JP2016521975A (ja) * 2013-05-15 2016-07-28 サンガモ バイオサイエンシーズ， インコーポレイテッド 遺伝的状態の処置のための方法および組成物
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
WO2017106537A2 (en) * 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
WO2017152015A1 (en) * 2016-03-04 2017-09-08 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073955A2 (en) * 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
KR20250141836A (ko) * 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
EA201891532A1 (ru) * 2015-12-28 2019-01-31 Новартис Аг Композиции и способы лечения гемоглобинопатий
US11564942B2 (en) * 2016-02-19 2023-01-31 The General Hospital Corporation Methods for generating universal and custom MHC/HLA-compatible hematopoietic progenitor cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521975A (ja) * 2013-05-15 2016-07-28 サンガモ バイオサイエンシーズ， インコーポレイテッド 遺伝的状態の処置のための方法および組成物
KR20160018425A (ko) * 2014-08-06 2016-02-17 차의과학대학교 산학협력단 조직적합성항원 유전자들의 교정을 통하여 구축한, 면역적합형 세포
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
WO2017106537A2 (en) * 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
WO2017152015A1 (en) * 2016-03-04 2017-09-08 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy

Also Published As

Publication number Publication date
IL274691A (en) 2020-06-30
CN111742049A (zh) 2020-10-02
EP3712268A4 (en) 2022-03-23
KR20200074954A (ko) 2020-06-25
JP2021503284A (ja) 2021-02-12
EP3712268A2 (en) 2020-09-23
US20200407713A1 (en) 2020-12-31
MX2020005235A (es) 2020-08-24
AU2018367792A1 (en) 2020-06-11
SG11202004529XA (en) 2020-06-29
WO2019098759A2 (ko) 2019-05-23
CA3082331A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
MX2020006015A (es) Composiciones y procedimientos para inhibir el agotamiento de celulas t.
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
ZA202002094B (en) Trispecific proteins and methods of use
EP4578507A3 (en) Compositions and methods for t cell engineering
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
MX2020006843A (es) Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MY171356A (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
PH12017501583B1 (en) Novel proteins specific for cd137
WO2016070166A3 (en) Messenger una molecules and uses thereof
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
SG10201804330YA (en) Engineered high-affinity human t cell receptors
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
EP3998341A3 (en) Adenoviral vectors

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3082331

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020527057

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018367792

Country of ref document: AU

Date of ref document: 20181116

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18877963

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018877963

Country of ref document: EP

Effective date: 20200616

WWW Wipo information: withdrawn in national office

Ref document number: 274691

Country of ref document: IL